© 2020 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
January 11, 2020
Novel drugs, value-based contracting, biosimilars, and regulatory activity addressing costs will be among the hot button issues in the coming year.
January 07, 2020
Payer education, evidence critical to providing cost-effective, beneficial treatment in pharmacogenetics.
September 05, 2019
What to expect for these high-dollar drugs.